The new Foundayo pill changes (almost) everything

For the last few years, there seemed to be a golden rule about prescription weight-loss medications: For the best results, you need to do an injection. But then a few months ago, an oral pill version of semaglutide became available that turned that rationale on its head. And now, the Food and Drug Administration (FDA) just approved another oral GLP-1 called Foundayo^®, which has the active ingredient orforglipron and is manufactured by Eli Lilly and Company. And if you’re thinking, aren’t they all the same at this point — different name, different manufacturer, no real difference? Well, you’d be wrong. Here’s why the addition of Foundayo is kind of a big deal, and who stands to gain (or rather lose) the most from it.

Foundayo is a new once-a-day prescription pill FDA-approved to help people with obesity (and some people with overweight plus additional medical conditions) lose weight, when combined with a healthy diet and exercise. In a study of 3,127 people with obesity or overweight with a comorbidity published last fall, those taking the highest dose of Foundayo lost an average of 25 pounds (or 11% of their starting body weight) after 72 weeks. They also improved their waist size, blood pressure, and cholesterol levels, and appeared to lose more fat than lean muscle and bone mass. 

Like the injectable weight-loss medications that came before it, Foundayo is in a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1s). It’s not the first weight-loss GLP-1 to come in a pill; that would be oral Wegovy, which was FDA-approved in December, 2025. But there’s a difference. 

Oral Wegovy’s active ingredient is semaglutide, which is a type of large molecule called a peptide. In order to be absorbed properly, oral semaglutide has to be taken on a completely empty stomach and you can’t eat or drink anything for 30 minutes after. 

But that’s not the case with Foundayo. That’s because the active ingredient in Foundayo is an entirely new molecule, called orforglipron. “All of the other GLP-1 medications to date have been peptides, whereas orforglipron is something called a small molecule,” says Dr. Debra Horn, D.O., professor and medical director of the Center for Obesity Medicine at UT Health Houston, who led a clinical trial of orforglipron. “They both stimulate the same GLP-1 receptor, but they have a different chemical structure.” As a result, you can take the Foundayo pill any time of day, with or without food and water.  

Like other GLP-1s, clinicians have people gradually go up in dose when they start taking Foundayo. They start with a 0.8 mg-dose pill once a day, then go up in dose every 30 days until they find the right dose that balances effectiveness and side effects. Available doses are: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg.

Like other GLP-1 receptor agonist medications, Foundayo works by mimicking a natural hormone (glucagon-like peptide-1) that your body releases after you eat. This hormone signals to your brain that you’re full, slows how quickly food leaves your stomach, and increases post-meal insulin to help regulate blood sugar levels. Together, those effects make you feel satisfied with smaller portions, reduce hunger between meals, and curb cravings. As a result, GLP-1s make it easier to eat fewer calories, leading to weight loss. 

That said, the mechanism by which the process is activated is slightly different for orforglipron (the active ingredient in Foundayo) than it is for other GLP-1s. “A peptide like semaglutide is basically a copy of a key that we made to fit into a lock, which is the body’s GLP-1 hormone receptor,” says Dr. Kerri Masutto, M.D., vice president of clinical and behavioral programs at Weight Watchers. “With orforglipron, it’s like there’s a button on the outside of that lock, and orforglipron hits the button just the right way and the lock pops open.” 

The catch is that it doesn’t unlock the receptor quite as fully as the peptide key does. “So while orforglipron absorbs better in the digestive system, it’s not quite as activating,” says Masutto. That helps explain the difference in effectiveness: People taking oral semaglutide (the Wegovy pill) lose about 14% of their body weight in a little over 16 months while those taking orforglipron lose about 11% in a similar time frame.

Injectable GLP-1s for weight loss (such as Zepbound) are more effective than either of the available oral GLP-1s, but Foundayo provides a feasible oral alternative that still achieves clinically significant weight loss. “If someone has a very high BMI, indicating severe obesity, it might be better for them to be on the injectables, because on average, they're going to lose more weight,” says Horn. But for those who aren’t looking to lose 20% of their weight, Foundayo might be a better choice.

There are other reasons why Foundayo could be an appealing choice for many people regardless of their starting weight — especially those who have an aversion to needles. The pills are also easier to store and travel with, since they don’t need to be refrigerated like injection meds. And it may seem counterintuitive, but the once-a-day dose might be simpler to manage than a weekly injection. “A daily medication can be better for some people, because it creates the daily habit of taking it at the same time every day, versus having to remember to take something once a week,” says Masutto. 

When choosing between GLP-1 pills, be sure to tell your clinician about any other medications you take frequently. “Since orforglipron is a small molecule, it's metabolized by a particular liver enzyme that has a number of drug interactions, while the semaglutide peptide is not,” says Masutto. “So Foundayo might not be the right choice for you if you take statin medication for high cholesterol, or if you regularly need to take antibiotics or antifungals, because there are some limitations to how high of a dose of Foundayo you can take if you're on these medications.”

The Foundayo pill comes with a similar set of side effects to other GLP-1 medications — namely, gastrointestinal upset, especially when first starting on the medication or increasing the dose. Eating smaller meals, avoiding high-fat foods, and stopping when you feel full can help prevent this. 

The most common symptoms when taking Foundayo are: 

• Belching

• Constipation

• Diarrhea

• Feeling tired

• Gas

• Hair loss

• Heartburn

• Headache

• Indigestion

• Nausea

• Stomach pain

• Swollen belly

• Vomiting

For a full list of Foundayo side effects, review the prescription insert.

More serious potential side effects include pancreatitis, severe stomach, kidney, or gallbladder problems, changes in vision (in people with type 2 diabetes), low blood sugar, and a higher chance of food or liquid entering your lungs during surgery or sedation. Like most modern GLP-1 medications, Foundayo also comes with a warning that it may cause thyroid tumors; people with a family or personal history of medullary thyroid carcinoma (MTC) or who’ve had multiple endocrine neoplasia syndrome type 2 (MEN 2) shouldn’t take it.

Foundayo is FDA-approved for weight loss and is currently available and in stock. Weight Watchers offers access to Foudayo through its Med+ program.*

It depends on whether or not you’re using insurance and the dose:

• The lowest dose of Foundayo, 0.8 mg, starts at $25 for a one-month supply for those with eligible commercial insurance and a savings card from the manufacturer.

• If you’re paying out of pocket, the price ranges from $149 a month to $399 a month, depending on the dose. 

• People with Medicare Part D could see a price of $50 per month starting in July 2026. Check the Foundayo site for details on when this may be available.

Foundayo (orforglipron) is a new FDA-approved oral GLP-1 for weight loss. It can result in significant weight loss with a simple-to-take, once-daily pill that may be easier for some to stick with than injections. It may lead to slightly less weight loss than other GLP-1 medications, but it offers more flexibility and more choice for people weighing their obesity treatment options.